For Liver Diseases

Introduction to Liver Diseases

Liver diseases account for approximately 2 million deaths per year worldwide, one million due to complications of cirrhosis and one million due to viral hepatitis and hepatocellular carcinoma. Among them, cirrhosis is currently the 11th most common cause of death globally and liver cancer is the 16th leading cause of death; combined, they account for 3.5% of all deaths worldwide^[1]. The most common liver diseases include nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease, chronic viral hepatitis, metabolic liver diseases, and cholestatic liver diseases. Given the lack of traditional chemical treatment options, there is an urgent need for new therapeutic strategies to combat liver disease.

Oligonucleotide Therapeutics for Liver Diseases

Recently, oligonucleotide therapeutics as a novel treatment approach have been widely used for a large number of liver diseases. These therapeutic oligonucleotides can target the expression of mRNA with high affinity and specificity through RNA-RNA or RNA-DNA base pairing, thereby controlling disease. Multiple druggable targets including miR-122, miR-132, miR-34, HSP 47, PNPLA3, STK25 etc., have emerged as susceptible molecular targets in the liver to treat various diseases^[2]. Thus, liver diseases may be treated effectively by modulating these susceptible molecular targets using novel therapeutic oligonucleotides. Currently, some preclinical and clinical studies are underway to evaluate the clinical efficacy and safety of different oligonucleotide therapeutics in the treatment of chronic liver diseases. In order to optimize their clinical efficacy, various strategies have been explored including chemical modifications of therapeutic oligonucleotides and developing effective drug delivery systems.

We are Developing Products for Liver Diseases

Alfa Chemistry is a pioneer in advancing biomedical technologies to improve human health. With a strong emphasis on independent innovation, we drive the discovery and development of cutting-edge drug delivery systems. We are developing oligonucleotide therapeutics for the treatment of liver diseases, and the following are a few examples of our products in development. If you are interested in these and need related technology and services, please contact us. We believe that good cooperation is the driving force behind new drugs.

Note: NASH means non-alcoholic steatohepatitis.

Our products and services are for research use only and cannot be used for any clinical purposes.

Online Inquiry

* Name

Phone

* Email

* Services & Products of Interest For Liver Diseases

Project Description

* Verification Code

Submit